![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1561540
¼¼°èÀÇ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå º¸°í¼ : À¯Çüº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)Medical Cyclotron Market Report by Type (Ring Cyclotron, Azimuthally Varying Field Cyclotron), Product Type, End User, and Region 2024-2032 |
ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 2¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 4¾ï 5,340¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2024³âºÎÅÍ 2032³â±îÁö 7.6%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¾Ï ¹ßº´·ü Áõ°¡, ¹æ»ç¼ºÀǾàǰÀÇ ¹ßÀü, ¾çÀüÀÚ¹æ»ç¼±´ÜÃþÃÔ¿µ(PET) ½ºÄµ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú Çõ½Å, ÀÇ·á ÀÎÇÁ¶ó È®´ë, ¿¬±¸ Ȱµ¿ Áõ°¡, ÇÙÀÇÇÐ ¹× ¿µ»óÁø´ÜÀ» ÃËÁøÇÏ´Â Á¤ºÎ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê µîÀÌ ½ÃÀå ¼ºÀåÀ» °ÈÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù.
¾Ï°ú ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå Á¶»ç º¸°í¼¿¡ µû¸£¸é ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä µ¿Çâ Áß Çϳª´Â Àü ¼¼°è ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ ÀÌȯÀ² Áõ°¡ÀÔ´Ï´Ù. ¾ÏÀº ¿©ÀüÈ÷ ¼¼°è ÁÖ¿ä »ç¸Á ¿øÀÎ Áß ÇϳªÀ̸ç Á¶±â ¹ß°ß ¹× Ä¡·á¸¦ À§ÇÑ Ã·´Ü Áø´Ü µµ±¸°¡ ÇÊ¿äÇϸç, 2022³â¿¡´Â 9¾ï 7õ¸¸ ¸íÀÌ »ç¸ÁÇϰí 5,350¸¸ ¸íÀÌ ¾Ï Áø´ÜÀ» ¹Þ°í »ì¾Æ°¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀº PET ½ºÄµ¿¡ »ç¿ëµÇ´Â ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ´Ù¾çÇÑ À¯ÇüÀÇ ¾ÏÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ ¸Å¿ì È¿°úÀûÀÔ´Ï´Ù. ¶ÇÇÑ ½ÉÇ÷°ü Áúȯ(CVD) ¹× ½Å°æ Áúȯ°ú °°Àº ¸¸¼º Áúȯ Áõ°¡·Î ÀÎÇØ Á¤¹Ð ¿µ»ó Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº Á¶±â Áø´Ü°ú È¿°úÀûÀÎ Ä¡·á °èȹÀ» Áß¿ä½ÃÇϱ⠶§¹®¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â °íǰÁú ¹æ»ç¼º µ¿À§¿ø¼Ò¿¡ ´ëÇÑ ¼ö¿ä°¡ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
¹æ»ç¼º ÀǾàǰÀÇ ¹ßÀü
¹æ»ç¼ºÀǾàǰÀº Áø´Ü°ú Ä¡·á ¸ñÀûÀ¸·Î ÇÙÀÇÇп¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù µé¾î º¸´Ù Á¤¹ÐÇϰí Ç¥ÀûÈµÈ ¹æ»ç¼ºÀǾàǰÀÌ °³¹ßµÇ¾î ¿µ»óÁø´Ü°ú Ä¡·áÀÇ Á¤È®¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼ºÀǾàǰÀÇ ±â¼ú Çõ½ÅÀº ±× Àû¿ë ¹üÀ§¸¦ È®ÀåÇÏ¿© Á¾¾çÇлӸ¸ ¾Æ´Ï¶ó ¼øÈ¯±âÇÐ, ½Å°æÇÐ µî º¸´Ù ±¤¹üÀ§ÇÑ ÁúȯÀÇ Áø´Ü°ú Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æ»ç¼ºÀǾàǰ ¿¬±¸¿¡ AI¿Í ¸Ó½Å·¯´×(ML)À» ÅëÇÕÇÏ¿© »õ·Î¿î ÈÇÕ¹° °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº »õ·Î¿î ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ±Ô¸ð È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.
ÇコÄɾî ÀÎÇÁ¶ó È®´ë ¹× ¿µ»óÁø´Ü¿¡ ´ëÇÑ ÅõÀÚ
ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë´Â ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. °ø°ø ±â°ü°ú ¹Î°£ ±â°ü ¸ðµÎ ÃÖ÷´Ü ¿µ»ó Áø´Ü Àåºñ¸¦ °®Ãá ÃÖ÷´Ü ÀÇ·á ½Ã¼³ °Ç¼³¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. º´¿ø ¹× Áø´Ü Ŭ¸®´ÐÀÇ PET ¹× PET-CT ¼¾ÅÍ ¼³Ä¡°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÙÀÇÇÐ ¹× Áø´Ü À̹Ì¡À» ÃËÁøÇϱâ À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â°ú ÀÚ±Ý Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿©·¯ ±¹°¡¿¡¼ ÷´Ü Áø´Ü µµ±¸¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí Çʼö ¹æ»ç¼º ÀǾàǰÀÇ Á¢±Ù¼ºÀ» º¸ÀåÇÏ´Â Á¤Ã¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. ¹æ»ç¼ºÀǾàǰÀº ÷´Ü ¿µ»óÁø´Ü¿¡ ÇÊ¿äÇÑ ¹æ»ç¼º µ¿À§¿ø¼Ò »ý»ê¿¡ ÇʼöÀûÀ̱⠶§¹®¿¡ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå Àü¸Á¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
IMARC GroupÀº °¢ ½ÃÀå ºÎ¹®ÀÇ ÁÖ¿ä µ¿Ç⠺м®°ú 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è, Áö¿ª ¹× ±¹°¡º° ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼´Â ½ÃÀåÀ» À¯Çüº°, Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÐ·ùÇÕ´Ï´Ù.
¸µ »çÀÌŬ·ÎÆ®·ÐÀÌ ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ½ÃÀåÀ» À¯Çüº°·Î »ó¼¼ÇÏ°Ô ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â ¸µ »çÀÌŬ·ÎÆ®·Ð°ú ¹æÀ§°¢ º¯µ¿ ÀÚ±âÀå(AVF) »çÀÌŬ·ÎÆ®·ÐÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é, ¸µ »çÀÌŬ·ÎÆ®·ÐÀÌ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ¾÷°è Åë°è¿¡ µû¸£¸é, ¸µ »çÀÌŬ·ÎÆ®·ÐÀº PET¿Í °°Àº ÷´Ü ¿µ»ó Áø´Ü ±â¼ú¿¡ ÇʼöÀûÀÎ °í¿¡³ÊÁö ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ý¼ºÇϴ Ź¿ùÇÑ ´É·ÂÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼³°è´Â ÀÔÀÚÀÇ ¿¬¼ÓÀûÀ̰í È¿À²ÀûÀÎ °¡¼ÓÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ´õ ³ôÀº ¼øµµ¿Í Àϰü¼ºÀ» °¡Áø ¹æ»ç¼º µ¿À§¿ø¼ÒÀÇ ³ôÀº ¼öÀ²À» ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¸µ »çÀÌŬ·ÎÆ®·ÐÀº ±× È¿À²¼ºÀ¸·Î ÀÎÇØ ÀÇ·á ½Ã¼³¿¡¼ ´ë·® »ý»ê¿¡ ÀûÇÕÇϸç, ÇʼöÀûÀÎ ¹æ»ç¼ºÀǾàǰÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Ã·´Ü ±â¼úÀº º¸´Ù ±¤¹üÀ§ÇÑ µ¿À§¿ø¼Ò¸¦ Áö¿øÇÏ¿© ½ÉÀ庴ÇÐ, ½Å°æÇÐ µî Á¾¾çÇп¡ ±¹ÇѵÇÁö ¾Ê´Â ´Ù¾çÇÑ ÀÇ·á¿ëµµ¿¡ ´ëÀÀÇÕ´Ï´Ù. ³ôÀº »ý»ê ´É·Â, ½Å·Ú¼º, ´Ù¿ëµµ¼ºÀ» °âºñÇÑ ¸µ »çÀÌŬ·ÎÆ®·ÐÀº ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå¿¡¼ ¼±Åùްí ÀÖ½À´Ï´Ù.
»çÀÌŬ·ÎÆ®·Ð 16-18MeV°¡ ¾÷°è ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼¿¡´Â Á¦Ç° À¯Çü¿¡ µû¸¥ ½ÃÀå ¼¼ºÐÈ ¹× ºÐ¼®µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »çÀÌŬ·ÎÆ®·Ð 10-12MeV, »çÀÌŬ·ÎÆ®·Ð 16-18MeV, »çÀÌŬ·ÎÆ®·Ð 19-24MeV, »çÀÌŬ·ÎÆ®·Ð 24MeV ÀÌ»óÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é »çÀÌŬ·ÎÆ®·Ð 16-18MeV°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
16-18MeV ¿¡³ÊÁö ¼öÁØÀÇ »çÀÌŬ·ÎÆ®·Ð¿¡ ´ëÇÑ ¼ö¿ä´Â ÁÖ·Î »ý»ê ´É·Â°ú ¿î¿µ È¿À²¼ºÀÇ ÃÖÀû ±ÕÇü¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, PET À̹Ì¡¿¡ ÇʼöÀûÀÎ ºÒ¼Ò 18Àº ÀÌ·¯ÇÑ »çÀÌŬ·ÎÆ®·Ð¿¡¼ »ý»êÇÒ ¼ö ÀÖ´Â ¸¹Àº ¹æ»ç¼º µ¿À§¿ø¼Ò Áß ÇϳªÀÔ´Ï´Ù. ¿¡³ÊÁö ¹üÀ§´Â ´ëÇü º´¿ø°ú »ó¾÷¿ë ¹æ»ç¼º ¾à±¹ ¼ö¿ä¸¦ ÃæÁ·½ÃŰ±â¿¡ ÃæºÐÇÑ ¼öÀ²·Î °í¼øµµ µ¿À§¿ø¼Ò¸¦ È¿À²ÀûÀ¸·Î »ý»êÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, ÀÌ »çÀÌŬ·ÎÆ®·ÐÀº ºñ¿ë È¿À²ÀûÀ̸ç ÀÇ·á ½Ã¼³¿¡ À¯¸®ÇÑ ÅõÀÚ ¼öÀÍ·üÀ» Á¦°øÇÕ´Ï´Ù. 16-18MeV »çÀÌŬ·ÎÆ®·ÐÀº ´Ù¾çÇÑ Áø´Ü ¹× Ä¡·á ¿ëµµ¸¦ Áö¿øÇÏ´Â ´É·Â°ú °áÇÕµÈ ´ÙÀç´Ù´ÉÇÔÀ¸·Î ÀÎÇØ ¾÷°è¿¡¼ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.
º´¿øÀÌ ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®À» Â÷ÁöÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ÃÖÁ¾ »ç¿ëÀÚº°·Î ½ÃÀåÀ» ¼¼ºÎÀûÀ¸·Î ºÐ·ùÇÏ°í ºÐ¼®ÇÕ´Ï´Ù. ¿©±â¿¡´Â º´¿ø, Áø´Ü¼¾ÅÍ, ¿¬±¸ ¹× Çмú ±â°ü, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. º¸°í¼¿¡ µû¸£¸é, º´¿øÀÌ °¡Àå Å« ºÎ¹®À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é º´¿øÀÌ °¡Àå Å« ÃÖÁ¾ »ç¿ëÀÚÀÌ¸ç °í±Þ Áø´Ü ¹× Ä¡·á ¼ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. º´¿ø ³» ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀº PET ¹× SPECT À̹Ì¡¿¡ »ç¿ëµÇ´Â Çʼö ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ »ý¼ºÇÕ´Ï´Ù. ÀÌ´Â ¾Ï, CVD, ½Å°æÁúȯ µî ´Ù¾çÇÑ Áúº´ÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. »çÀÌŬ·ÎÆ®·ÐÀ» º´¿ø ³»¿¡ ¼³Ä¡Çϸé ÀÌ·¯ÇÑ ¹æ»ç¼ºÀǾàǰÀ» Àû½Ã¿¡ ¾ÈÁ¤ÀûÀ¸·Î °ø±ÞÇÒ ¼ö ÀÖ¾î ȯÀÚ Ä¡·á¿Í Ä¡·á °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹æ»ç¼º µ¿À§¿ø¼Ò ÀÚü »ý»ê Áõ°¡ Ãß¼¼¿¡ µû¶ó º´¿øÀº ¿ÜºÎ °ø±Þ¾÷ü¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙÀÌ°í ¿î¿µ ºñ¿ëÀ» Àý°¨Çϸç ÇÙÀÇÇÐ ºÎ¼ÀÇ È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ·¯½Ã¾Æ, ±âŸ), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ, Àεµ³×½Ã¾Æ, ±âŸ), ¶óƾ¾Æ¸Þ¸®Ä«(ºê¶óÁú, ¸ß½ÃÄÚ, ±âŸ), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« µî ÁÖ¿ä Áö¿ª ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. º¸°í¼¿¡ µû¸£¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀÇ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.
ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·Ð ½ÃÀå ºÐ¼®¿¡ µû¸£¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ƯÈ÷ Áß±¹, ÀϺ», Àεµ¿Í °°Àº ±¹°¡¿¡¼ źźÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë·Î ÀÎÇØ ÷´Ü Áø´Ü ¹× Ä¡·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ÁÖ¿ä Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ÅõÀÚ Áõ°¡¿Í À¯¸®ÇÑ Á¤Ã¥Àº ÀÇ·á ½Ã¼³¿¡¼ ÀÇ·á¿ë »çÀÌŬ·ÎÆ®·ÐÀÇ Ã¤ÅÃÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼ ¾Ï ¹× ±âŸ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ ¿µ»ó Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä »çÀÌŬ·ÎÆ®·Ð Á¦Á¶¾÷üÀÇ Á¸Àç¿Í ÇÙÀÇÇÐ ¿¬±¸ ¹× °³¹ß(R&D)ÀÌ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ÀÌ Áö¿ªÀÇ °Á¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
(Âü°í·Î, ÀÌ´Â ÁÖ¿ä ±â¾÷ÀÇ ÀϺΠ¸ñ·ÏÀ̸ç, Àüü ¸ñ·ÏÀº º¸°í¼¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù)
The global medical cyclotron market size reached US$ 230.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 453.4 Million by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032. The increasing cancer prevalence, advancements in radiopharmaceuticals, rising demand for positron emission tomography (PET) scans, technological innovations, expanding healthcare infrastructure, growing research activities, and supportive government initiatives promoting nuclear medicine and diagnostic imaging are some of the key factors strengthening the market growth.
Rising prevalence of cancer and chronic diseases
Medical cyclotron market research report shows that one of the primary trends driving the market is the increasing incidence of cancer and other chronic diseases worldwide. Cancer remains one of the leading causes of death globally, necessitating advanced diagnostic tools for early detection and treatment. In 2022, there were 9.7 million deaths and 53.5 million living with a cancer diagnosis. Medical cyclotrons play a crucial role in producing radioisotopes used in PET scans, which are highly effective in detecting various types of cancers at an early stage. Additionally, the escalating prevelance of chronic diseases such as cardiovascular disorders (CVD) and neurological conditions has increased the demand for precise diagnostic imaging techniques. As healthcare systems emphasize early diagnosis and effective treatment plans, the need for reliable and high-quality radioisotopes is bolstering the medical cyclotron market growth.
Advancements in radiopharmaceuticals
Radiopharmaceuticals play a crucial role in nuclear medicine for both diagnostic and therapeutic purposes. Recent advancements have led to the development of more precise and targeted radiopharmaceuticals, enhancing the accuracy and effectiveness of diagnostic imaging and treatments. This innovation in radiopharmaceuticals has expanded their application scope, enabling the diagnosis and treatment of a broader range of diseases beyond oncology, including cardiology and neurology. Moreover, the integration of AI and machine learning (ML) in radiopharmaceutical research has spurred the development of new compounds, improving patient outcomes. These advancements necessitate the production of novel radioisotopes, thereby providing an impetus to the medical cyclotron market size.
Expanding healthcare infrastructure and investments in diagnostic imaging
The expansion of healthcare infrastructure significantly contributes to the market growth. Both public and private organizations are making significant investments in the construction of cutting-edge medical facilities outfitted with cutting-edge diagnostic imaging equipment. The increasing establishment of PET and PET-CT centers in hospitals and diagnostic clinics is aiding in market expansion. Moreover, favorable government initiatives and funding to promote nuclear medicine and diagnostic imaging are further supporting the market growth. For instance, various countries are implementing policies to improve access to advanced diagnostic tools and ensure the availability of essential radiopharmaceuticals. This is positively impacting the medical cyclotron market outlook because they are essential for producing the radioisotopes needed for these cutting-edge imaging methods.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, product type, and end user.
Ring cyclotron accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes ring cyclotron and azimuthally varying field (AVF) cyclotron. According to the report, ring cyclotron represented the largest segment.
As per the medical cyclotron industry statistics, ring cyclotrons dominate the market due to their superior capabilities in producing high-energy radioisotopes essential for advanced diagnostic imaging techniques like PET. Their design allows for continuous and efficient acceleration of particles, resulting in higher yields of radioisotopes with greater purity and consistency. Ring cyclotrons are well-suited for large-scale production in medical facilities owing to their efficiency, which guarantees a consistent supply of essential radiopharmaceuticals. Additionally, their advanced technology supports a wider range of isotopes, catering to diverse medical applications beyond oncology, such as cardiology and neurology. The combination of high production capacity, reliability, and versatility positions ring cyclotrons as the preferred choice in the medical cyclotron market.
Cyclotron 16-18 MeV holds the largest share of the industry
A detailed breakup and analysis of the market based on the product type have also been provided in the report. This includes cyclotron 10-12 MeV, cyclotron 16-18 MeV, cyclotron 19-24 MeV, and cyclotron 24 MeV and above. According to the report, cyclotron 16-18 MeV accounted for the largest market share.
The demand for cyclotrons with 16-18 MeV energy levels is mainly driven by their optimal balance between production capacity and operational efficiency. Fluorine-18, which is essential for PET imaging, is among the many radioisotopes that can be produced by these cyclotrons. The 16-18 MeV energy range allows for efficient production of high-purity isotopes with sufficient yield to meet the demands of both large hospitals and commercial radio pharmacies. Additionally, these cyclotrons are cost-effective, offering a favorable return on investment for medical facilities. Their versatility, combined with the ability to support diverse diagnostic and therapeutic applications, makes 16-18 MeV cyclotrons the preferred choice in the industry.
Hospitals represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic centers, research and academic institutes, and others. According to the report, hospitals represented the largest segment.
Medical cyclotron market insights exhibit hospitals as the biggest end users with their critical role in providing advanced diagnostic and therapeutic services. Medical cyclotrons in hospitals produce essential radioisotopes used in PET and SPECT imaging, which are pivotal for diagnosing and monitoring various diseases, including cancer, CVDs, and neurological disorders. The integration of cyclotrons within hospital settings ensures a timely and reliable supply of these radiopharmaceuticals, enhancing patient care and treatment outcomes. Furthermore, the growing trend of in-house production of radioisotopes allows hospitals to reduce dependence on external suppliers, lower operational costs, and improve the efficiency of their nuclear medicine departments.
Asia Pacific leads the market, accounting for the largest medical cyclotron market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific represents the largest regional market for medical cyclotron.
Medical cyclotron market analysis revealed Asia Pacific as the leading region due to robust healthcare infrastructure expansion, particularly in countries like China, Japan, and India, which boosts the demand for advanced diagnostic and therapeutic technologies. Increasing government investments and favorable policies support the adoption of medical cyclotrons in healthcare facilities. Additionally, the rising prevalence of cancer and other chronic diseases in the region amplifies the need for advanced imaging and treatment solutions, further driving market growth. The presence of leading cyclotron manufacturers and growing research and development (R&D) activities in nuclear medicine also contribute to the region's dominance.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)